# TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

> **NCT05862324** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Triumvira Immunologics, Inc.** · enrollment: 113 (estimated)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **BIOLOGICAL:** TAC01-CLDN18.2

## Key facts

- **NCT ID:** NCT05862324
- **Lead sponsor:** Triumvira Immunologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-23
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 113 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862324, "TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05862324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*